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ABSTRACT:
The molecular chaperone Heat Shock Protein 90 (Hsp90) is essential for the function 
of various oncoproteins that are vital components of multiple signaling networks 
regulating cancer cell proliferation, survival, and metastasis. Hsp90 chaperone 
function is coupled to its ATPase activity, which can be inhibited by natural products 
such as the ansamycin geldanamycin (GA) and the resorcinol radicicol (RD). These 
compounds have served as templates for development of numerous natural product 
Hsp90 inhibitors. More recently, second generation, fully synthetic Hsp90 inhibitors, 
based on a variety of chemical scaffolds, have also been synthesized. Together, 18 
natural product and synthetic Hsp90 inhibitors have entered clinical trial in cancer 
patients. To successfully develop Hsp90 inhibitors for oncology indications it is 
important to understand the factors that influence the susceptibility of Hsp90 to these 
drugs in vivo. We recently reported that Casein Kinase 2 phosphorylates a conserved 
threonine residue (T22) in helix-1 of the yeast Hsp90 N-domain both in vitro and in vivo. 
Phosphorylation of this residue reduces ATPase activity and affects Hsp90 chaperone 
function. Here, we present additional data demonstrating that ATP binding but not 
N-domain dimerization is a prerequisite for T22 phosphorylation. We also provide 
evidence that T22 is an important determinant of Hsp90 inhibitor sensitivity in yeast 
and we show that T22 phosphorylation status contributes to drug sensitivity in vivo.
INTRODUCTION
Molecular chaperones are involved in protein 
folding and homeostasis [1]. Hsp90 is an essential, 
evolutionarily-conserved molecular chaperone that is 
ubiquitously expressed both in normal and cancer cells 
[2-5]. While Hsp90 has been shown to bind to and prevent 
the aggregation of a wide range of proteins [6], the list of 
proteins that require active chaperoning by Hsp90 is more 
restricted (www.picard.ch/downloads/Hsp90interactors.
pdf), and is comprised primarily of key components of 
numerous signal transduction pathways. In cancer cells, 
Hsp90 plays a vital role in protecting selected mutated, 
over-expressed and/or deregulated oncoproteins from 
misfolding and degradation [7, 8]. Therefore it is not 
surprising that multiple Hsp90 inhibitors are being 
actively evaluated in the clinic (Table 1) [9].
Hsp90 is dimeric and each protomer can be divided 
into three domains (Figure 1) [10, 11]: i) an N-terminal 
domain, containing nucleotide, co-chaperone (proteins 
that assist the chaperone activity of Hsp90), and drug 
binding sites; ii) a middle (M) domain, which provides 
binding sites for client proteins and co-chaperones; iii) 
a C-terminal domain containing a dimerization motif, 
a second inhibitor binding region and binding sites for 
additional co-chaperones [12-14]. N and M domains 
are connected by an unstructured charged-linker region 
of  significant  but  variable  length,  which  provides 
conformational flexibility to the protein [15, 16].
Hsp90 chaperone function is coupled to its ability 
to bind and hydrolyze ATP, which in turn promotes an 
ordered series of conformational changes known as the Oncotarget 2011; 2:  407 - 411 402 www.impactjournals.com/oncotarget
Table 1: Current Hsp90 inhibitors in clinical trials.
    * non-small cell lung cancer (NSCLC), small cell lung cancer  (SCLC), chronic  
       lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), or B-cell  
       prolymphocytic leukemia (B-PLL), acute myelogenous leukemia (AML), 
       myelodysplastic syndrome (MDS), chronic myelogenous leukemia (CML), 
       gastrointestinal stromal tumor (GIST), metastatic breast cancer (MBC), 
      multiple myeloma (MM), hormone-resistant prostate cancer (HRPC).
Inhibitor Phase Route Indication* Structure Imaging Combination
drug(s)
Source
Retaspimycin
hydrochloride
(IPI-504)
II i.v.
Advanced 
dedifferentiated 
liposarcoma, NSCLC 
patients with ALK 
translocations
- - Infinity
IPI-493 I oral
Advanced solid 
tumors, hematologic 
malignancies
- - - Infinity
AUY922 I/II i.v.
Advanced solid 
malignancies, MBC, 
stage IIIB-IV NSCLC, 
advanced gastric 
cancer, metastatic 
colorectal cancer
89Zr-trastuzumab, 
VEGF-89ZR-
bevacizumab 
PET imaging 
Trastuzumab, 
erlotinib, 
capecitabine, 
cetuximab
Novartis
Ganetespib
(STA-9090)
I/II i.v.
AML, MDS, CML, 
or myeloproliferative 
disorders, stage 
IIIB or IV NSCLC, 
GIST, colorectal 
cancer, SCLC, 
esophagogastric 
cancer, metastatic 
ocular melanoma, 
metastatic pancreatic 
cancer, metastatic 
HRPC, MBC, solid 
tumors
- - Docetaxel Synta
KW-2478 I/II i.v. MM - Bortezomib Kyowa Hakko Kirin
AT13387 I/II
oral
i.v.
GIST, metastatic solid 
tumors - Imatinib Astex Therapeutics
HSP990 I oral advanced solid tumors - - - Novartis
MPC-3100 I oral
Cancer patients who 
have failed other 
treatments
- - - Myrexis, Inc.
DS-2248 I oral Advanced solid tumors - - - Daiichi Sankyo Inc.
Debio 0932 I oral
Advanced solid tumors 
or lymphoma
- - Debiopharm/Curis
PU-H71 - i.v.
Breast cancer, prostate 
cancer or lymphoma
[124I]-PU-H71 
PET imaging
-
Memorial Sloan-
Kettering Cancer 
CenterOncotarget 2011; 2:  407 - 411 403 www.impactjournals.com/oncotarget
Residues 
yHsp90 yHsc90 hHsp90a hHsp90b Protein Kinase Reference
N/A N/A T5* N/A Ds-DNA activated protein
kinase
[43]
N/A N/A T7* N/A Ds-DNA activated protein
kinase
[43]
T22* T22 Y36 Y31 CaseinkinaseII [33]
Y24* Y24 Y38* Y33 Swe1/Wee1 [29]
S36 S36 S50 S45* UNKNOWN [44, 45]
N/A  N/A  S52* N/A UNKNOWN [46]
S39 S39 S53 S48* UNKNOWN [44, 45]
Y47 Y47 Y61 Y56* UNKNOWN [47-50]
S49 N/A S63*§ S58* CaseinkinaseII [49, 51]
S51 S51 T65* T60 CaseinkinaseII [51]
N/A N/A S68* S63 CaseinkinaseII [51]
T58 T58 S72* S67 CaseinkinaseII [51]
N/A N/A T88* T83 PKA [52]
N/A N/A T90* T85 UNKNOWN [53]
Y184 Y184 Y197 Y192* UNKNOWN [48]
S198 S198 S211† S206 PKA, PKG [54]
N/A N/A S231* S226* CaseinkinaseII [31, 55, 56]
N/A N/A S252* N/A UNKNOWN [57]
N/A N/A S263* S255* CaseinkinaseII,B-Raf [31, 55, 56, 58]
N/A N/A N/A S261*†§ UNKNOWN [49, 57, 59-64]
N/A N/A Y284* Y276* UNKNOWN [50, 65]
S282* S278 N/A N/A UNKNOWN SGD
T273 T269 T293* T285* UNKNOWN [66]
T285 T281 T305 T297* UNKNOWN [67]
S297* S293 N/A N/A UNKNOWN SGD
Y289 Y285 Y309 Y301* c-Src (does notexist inyeast) [68]
Y293 Y289 Y313§ Y305* UNKNOWN [69]
S295 S291 S315 S307* UNKNOWN [63]
S297 S293 T317* T309* UNKNOWN [66]
S334* S330 N/A N/A UNKNOWN SGD
S379* S375 S399 S391* UNKNOWN SGD, [49, 59,65]
T443* T429 S453§ S445* UNKNOWN SGD, [59]
N/A N/A N/A T446§ UNKNOWN [49, 59]
N/A N/A S460 S452* PKA [54]
N/A N/A Y466* N/A UNKNOWN [50], PhosphoSitePlus®
S456 S452 S476§ S468 UNKNOWN [49]
N/A N/A N/A S482§ UNKNOWN [46]
Y472 Y468 Y492* Y484* UNKNOWN [45, 70], PhosphoSitePlus®
Y473 Y469 Y493* Y485* UNKNOWN PhosphoSitePlus®
S478 S474 T495§ S490 UNKNOWN [45]
T502 T498 N/A T514§ UNKNOWN [45]
Y508 Y504 Y498 Y520§ UNKNOWN [45]
T520 T516 T540 S532* UNKNOWN [63]
N/A N/A T566§ N/A UNKNOWN [49]
S568 S564 S589* S581 UNKNOWN [66]
N/A N/A Y604*§ Y596* UNKNOWN [71]PhosphoSitePlus®
Y606 Y602 Y627*§ Y619* UNKNOWN PhosphoSitePlus®
S616* S612 N/A N/A UNKNOWN SGD
S619* S615 N/A N/A UNKNOWN SGD
N/A N/A S641§ N/A UNKNOWN [49]
S657* S653 S677 S668 UNKNOWN [72]
S663* S659 N/A N/A UNKNOWN [72]
N/A N/A Y689* Y681 UNKNOWN [50], PhosphoSitePlus®
N/A N/A T725* N/A UNKNOWN [63]
N/A N/A S726* S718* UNKNOWN [63]
Table 2: Hsp90 phosphorylation sites and identified kinases. Yeast (Hsc82, Hsp82) and human (Hsp90α, Hsp90β) phosphorylation 
residues are marked by an asterisk (*); orthologue residue is also shown when present. These phosphorylation sites were taken from 
published literature and the websites PhosphoSitePlus® (http://www.phosphosite.org/) and Saccharomyces Genome Database (SGD) 
(http://www.yeastgenome.org/). Marked phosphorylation residues (†) were identified in rat and (§) mouse Hsp90.Oncotarget 2011; 2:  407 - 411 404 www.impactjournals.com/oncotarget
chaperone cycle that is necessary for Hsp90’s chaperone 
function [17, 18]. Hsp90 inhibitors currently in clinical 
evaluation all share the property of preventing the 
chaperone cycle by occupying Hsp90’s N-domain ATP 
binding pocket [19, 20]. The regulation of eukaryotic 
Hsp90 function is complex and depends on several 
factors, including the regulated interaction of specific co-
chaperones (e.g., Aha1 stimulates Hsp90 ATPase activity, 
whereas p23/Sba1 and Hop/Sti1 inhibit ATP hydrolysis 
[21, 22]), and various post-translational modifications [23, 
24]. A more detailed understanding of the mechanics of 
Hsp90 regulation in normal and cancer cells may provide 
additional therapeutic strategies to effectively inhibit this 
protein.
HSP90 PHOSPHORYLATION 
REGULATES CHAPERONE FUNCTION
Hsp90 is subject to several post-translational 
modifications,  including  phosphorylation,  acetylation, 
and S-nitrosylation, that contribute to Hsp90 regulation, 
although regulation of these processes within the cell is 
not well understood [3, 4]. While Hsp90 acetylation and 
S-nitrosylation have been identified more recently [23, 
24], Hsp90 phosphorylation was first reported in the early 
1980s [25]. 
Hsp90 is a substrate for several serine/threonine 
and tyrosine kinases, including double-stranded DNA-
dependent protein kinase, Akt, B-Raf, Protein Kinase A 
(PKA), Casein Kinase 2 (CK2), c-Src and Wee1 [3, 4, 
26] (Table 2). These kinases are also clients of Hsp90, 
suggesting the possible existence of complex feedback 
loops whereby these kinases may modulate their own 
chaperoning and functional activity. Indeed, others have 
suggested that client binding to Hsp90 may directly 
influence its chaperone activity [2, 27]. Previous work 
has shown that brief exposure of cells to okadaic acid, 
a serine/threonine phosphatase inhibitor, leads to Hsp90 
threonine hyperphosphorylation and is accompanied 
by decreased Hsp90 association with its client kinase 
v-Src [28]. These data suggest that Hsp90 threonine 
phosphorylation is tightly regulated and therefore is likely 
to impact chaperone function. 
We reported recently that Wee1Swe1 phosphorylates 
a conserved tyrosine residue (Y24 in yeast Hsp90 and 
Y38 in human Hsp90α) in the N-domain of Hsp90 in a 
cell cycle-dependent manner [29]. Interestingly, deletion 
of Swe1 in yeast or pharmacologic inhibition of Wee1 in 
cancer cells confers hypersensitivity to Hsp90 inhibition 
Figure 1: The Hsp90 chaperone cycle. Hsp90 is a dimer of two monomers, each containing an N-domain (“N”, blue); a charged 
linker (“CL”, red); an M-domain (“M”, green); and a C-domain (“C”, brown). The ATP lid (purple) in the N-domain alters conformation 
upon ATP binding to the N-terminal domains of the “open” conformation, promoting “lid” closure followed by transient dimerization of 
the N-domains. Subsequent structural changes result in the “closed and twisted” conformation that is competent for ATP hydrolysis. The 
co-chaperones Sti1 and Cdc37, and pharmacologic inhibitors such as those discussed in the text, slow or block, respectively, the chaperone 
cycle at an early stage, while the co-chaperone Aha1 enhances the ATPase activity of Hsp90 by assisting the extensive and energy-intensive 
conformational changes necessary to achieve competence for ATP hydrolysis. The co-chaperone p23 stabilizes a late Hsp90 conformation 
and slows, but does not block, the rate of ATP hydrolysis. For more details, please see [4].
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[29].
CK2 DEPENDENT PHOSPHORYLATION 
OF HSP90 
CK2 is a serine/threonine protein kinase and an 
Hsp90 client [30] that phosphorylates multiple serine and 
threonine residues in human Hsp90α (hHsp90α) and yeast 
Hsp82 (yHsp90) [31, 32]. Recently, we used S. cerevisiae 
to show that CK2 phosphorylates a single conserved 
threonine residue (T22) in the N-domain of yHsp90 both 
in vitro and in vivo [33]. T22 resides in helix-1 of the 
Hsp90 N-domain that, together with other adjacent amino 
acids, is involved in an important hydrophobic interaction 
with the ATPase catalytic loop in the M-domain that helps 
to establish Hsp90’s ATP hydrolysis-competent state. 
The functional importance of T22 was uncovered 
initially in a genetic screen, where its mutation to 
isoleucine affected the chaperoning of v-Src and 
glucocorticoid receptor (GR) in yeast [34]. Subsequent 
work demonstrated that the T22I mutant has 6-fold 
higher ATPase activity compared to WT yHsp90 [35]. 
In contrast, we have shown that mutation of T22 to non-
phosphorylatable alanine (T22A) did not affect its ATPase 
activity, while phospho-mimetic mutation of this residue 
to glutamic acid (T22E) reduced ATPase activity by 60% 
compared to WT yHsp90. Nevertheless, both mutants in 
yeast  and  the  equivalent  mutations  in  hHsp90α  (T36A 
and T36E) affected Hsp90-dependent chaperoning of 
kinase (v-Src, Mpk1/Slt2, Raf-1, ErbB2 and CDK4) and 
non-kinase  (cystic  fibrosis  transmembrane  conductance 
regulator protein and GR) clients [33]. 
To explore further whether ATP binding is a 
prerequisite for T22 phosphorylation, we examined the 
ability of CK2 to phosphorylate two conformationally 
distinct Hsp90 N-domain mutants. CK2 was able to 
efficiently phosphorylate yHsp90-E33A, which binds ATP 
equivalently to wild-type but, upon ATP binding, favors 
a “closed” (N-domain dimerized) conformation (i.e., is 
unable to hydrolyze ATP). However, CK2 was unable 
to phosphorylate yHsp90-D79N, which cannot bind 
ATP and thus favors an “open” (N-domain undimerized) 
conformation (Figure 2A). Since T22 is not accessible 
to solvent once ATP-dependent N-domain dimerization 
has occurred [18], these data suggest that ATP binding 
to the open conformation of Hsp90 sets in motion rapid 
Figure 2. A) CK2-mediated threonine phosphorylation of the N-domain of WT, T22A, E33A and D79N yHsp90-His6 in vitro. Threonine 
phosphorylation was detected with a pan anti-phosphothreonine antibody. For more details, please see [33]. B) WT, T22A, and T22E 
yHsp90-His6-expressing yeast were treated with the proteasome inhibitor MG132 (50 mM for 1 h), and yHsp90 ubiquitination was assessed 
using anti-ubiquitin antibody to probe salt-stripped (0.5 M NaCl) His6 pull-downs.
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conformational change within and adjacent to helix-1 
that is a prerequisite for CK2-mediated phosphorylation. 
Indeed, a recent study of the bacterial ortholog of Hsp90, 
HtpG, confirms that this region of the N-domain undergoes 
very rapid conformational change upon ATP binding 
that  significantly  precedes  ATP-induced  N-domain 
dimerization [35, 36] Since T22 phosphorylation slows the 
rate of ATP hydrolysis without affecting ATP binding, it is 
possible that eukaryotic cells utilize this post-translational 
modification to adjust the rate of the Hsp90 cycle to meet 
the optimal chaperone requirements of individual client 
proteins. 
We showed previously that phosphorylation of Y24 
is a signal for Hsp90 polyubiquitination and degradation 
by cytoplasmic proteasomes [33]. We explored the 
possibility that T22 phosphorylation of yHsp90 may serve 
a similar purpose. Yeast expressing WT Hsp90 as well as 
the phospho mutants (T22A and T22E) were treated with 
the proteasome inhibitor MG132 (50 µM for 1h). This 
resulted in equivalent accumulation of polyubiquitinated 
yHsp90 in each case (Figure 2B). Therefore, unlike Y24, 
T22 phosphorylation is not likely to be a determinant of 
Hsp90 degradation. Instead, one can speculate that T22 
phosphorylation occurs dynamically to allow for the fine-
tuning of chaperone activity in response to environmental 
cues.
CK2 PHOSPHORYLATION 
OF THREONINE 22 IMPACTS 
CHAPERONING OF HEAT SHOCK 
FACTOR (HSF)
The phospho-mimetic T22E mutant, like T22I, 
is temperature sensitive whereas T22A-expressing 
yeast grow like wild-type cells at elevated temperature 
(Figure  3A).  This  phenotype  may  reflect  the  different 
ATPase activities of these mutants, since it is generally 
accepted that Hsp90 binding serves to down-regulate 
HSF transcriptional activity [37]. Mutations of Hsp90 that 
Figure 3. A) Yeast expressing WT yHsp90-His6 or the phospho mutants T22A and T22E, as well as T22I, were grown to mid-log phase 
(107 cells/ml) and then a 1:10 dilution series was spotted on YPDA agar. The plates were incubated either at 27˚C or 37˚C for 3 days to test 
for temperature sensitivity. B) Yeast cells expressing WT yHsp90-His6 or phospho mutants T22A and T22E, or T22I, were transformed with 
a Heat Shock Element (HSE)-lacZ reporter. HSE activity was measured in unstressed (light bars) and heat shocked (40 min at 39˚C, dark 
bars) cells. The data are expressed as mean +/- standard deviation derived from four independent experiments.
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compromise its chaperone function, or Hsp90 inhibitor 
administration, lead to strong induction of Hsf1 activity in 
yeast, even in the absence of heat shock [38]. 
To examine the importance of T22 in Hsp90 
modulation of the heat shock response, we measured Hsf1 
activity in yHsp90 T22A (normal ATPase activity), T22E 
(reduced ATPase activity) and T22I (elevated ATPase 
activity)-expressing yeast cells by transforming them 
with a heat shock element HSE-lacZ reporter plasmid. We 
confirmed that yHsp90-T22I displayed a higher basal and 
heat-induced (39˚C for 40 min) Hsf1 activity compared 
to WT cells [39] (Figure 3B), while Hsf1 activity 
was  significantly  diminished  in  the  phospho-mimetic 
yHsp90-T22E mutant. At the same time, Hsf1 activity 
in yHsp90-T22A mutant yeast was equivalent to that of 
yeast expressing WT yHsp90. These data suggest that the 
ability of yHsp90 to regulate Hsf1 closely parallels its 
inherent ATPase activity, but that temperature sensitivity 
itself is not an accurate predictor of the impact of these 
Hsp90 mutations on the heat shock response.
PHOSPHORYLATION OF THREONINE 
22 CONFERS INCREASED SENSITIVITY 
TO HSP90 INHIBITORS 
There are currently 18 Hsp90 inhibitors in various 
stages of clinical evaluation as targeted anti-cancer agents. 
Uncovering modifications to Hsp90 that might enhance 
sensitivity to these inhibitors at the cellular level would 
certainly aid their continued clinical development. To that 
end, we have examined the sensitivity of T22 mutants 
to Hsp90 inhibitors. We expressed non-phospho (T22A) 
and phospho-mimetic (T22E) Hsp90 mutants, as well as 
yHsp90-T22I, as the sole Hsp90 species in the PP30 yeast 
strain lacking the pleiotropic drug resistance pump, Pdr5 
[40, 41]. Although the S. cerevisiae genome contains 30 
plasma membrane ATP-binding cassette (ABC) proteins 
[42], Pdr5 has been identified as the major mediator of 
Hsp90 inhibitor efflux [40, 41]. 
Yeast cells were grown to exponential phase and 
were spotted at 107, 106 and 105 cells/ml on YPDA plates 
containing 40 or 60 µM GA or radicicol (RD). The 
synthetic Hsp90 inhibitors, ganetespib (formerly STA-
Figure 4: PP30 pdr5∆ yeast strain expressing only WT y Hsp90, yHsp90-T22I, yHsp90-T22A, or yHsp90-T22E were 
grown to mid-log phase (107 cells/ml) and then a 1:10 dilution series was spotted on YPDA agar containing indicated 
concentrations of the Hsp90 inhibitors geldanamycin (GA), radicicol (RD), SNX2112, or STA-9090. Plates were incubated 
at 25˚C for 4 days.
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9090, Synta Pharmaceuticals) and SNX-2112 (Serenex/
Pfizer) were also included in these assays (at 60 or 80 µM). 
Our data show that the drug sensitivity of y-Hsp90-T22A-
expressing yeast was equivalent to or less than that of 
yeast expressing WT yHsp90. In contrast, yeast expressing 
yHsp90-T22I were uniformly hypersensitive to all of the 
Hsp90 inhibitors examined (Figure 4A, B). Interestingly, 
yeast expressing the phospho-mimetic yHsp90-T22E 
were also more sensitive than either WT or yHsp90-T22A-
expressing yeast to the four Hsp90 inhibitors (Figure 4A, 
B). However, this increased sensitivity was evident only 
at higher drug concentrations. These data identify T22 as 
an important determinant of Hsp90 inhibitor sensitivity 
in yeast and suggest that T22 phosphorylation status may 
contribute to drug sensitivity in vivo. 
CONCLUDING REMARKS
Hsp90 phosphorylation has been known for nearly 
30 years [25], however only recently are we beginning to 
appreciate its significance in fine-tuning Hsp90 chaperone 
activity [4]. Our recent work has demonstrated that the 
Hsp90 client kinase CK2 phosphorylates a conserved 
threonine residue (T22) in the N-domain of yHsp90. 
This residue participates in a hydrophobic interaction 
with lysine 378 of the catalytic loop in the Hsp90 middle 
domain, helping to stabilize the ATPase-competent state 
induced by ATP binding to the N-domain. Phospho-
mimetic mutation of this residue in both yeast and human 
Hsp90 alters chaperone function (see Figure 5 and [33]). 
Here, we have provided additional data showing that 
mutation of this residue impacts both the heat shock 
response and sensitivity to Hsp90 inhibitors. 
It is unlikely that the regulation of Hsp90 function, 
in all its complexity, is universal for all client proteins of 
this chaperone. Indeed, a recent report [2] has suggested 
that different clients and co-chaperone complexes 
can be accommodated by subtly different Hsp90 
conformational states. Perhaps phosphorylation of Hsp90, 
at T22 and additional amino acid residues, participates in 
modulating the equilibrium among these client-dependent 
conformational states. 
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